Corcept Therapeutics

Corcept Therapeutics relacorilant

In the graph: all 16 documents (129 pages).

Application: NDA 219398
Ticker: CORT
Product: relacorilant
Disease area: Cushing's syndrome
Response path: Response in progress
Complete Response Letters: January 28, 2026
Where it stands: CRL (efficacy); FDA later published the letter. Response in progress; securities litigation pending.

From FDA letters and SEC filings. Not investment or medical advice.

Group by

Build queue · replay at pipeline speed